Table 4.
The domains SF-12 questionnaire at the beginning and after 12 weeks of intervention in people with polycystic ovary syndrome
| Variables | Intervention group N = 28 | Control group N = 24 | 95% CI | P** | P*** | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Physical score | ||||||
|
Baseline End of trial Change |
66.75 ± 12.61 68.95 ± 14.23 2.19 ± 10.79 |
65.54 ± 17.94 73.07 ± 18.91 7.53 ± 18.02 |
-7.33 -13.36 -13.47 |
9.76 5.12 2.80 |
0.777 0.375 0.194 |
|
| P* | 0.291 | 0.052 | ||||
| Mental score | ||||||
|
Baseline End of trial Change |
55.06 ± 13.31 55.00 ± 15.72 -0.37 ± 13.96 |
54.72 ± 18.17 59.16 ± 19.29 4.44 ± 13.92 |
-8.55 -13.92 -12.67 |
9.23 5.58 3.04 |
0.939 0.395 0.224 |
|
| P* | 0.891 | 0.132 | ||||
| Cronbach’s alpha | ||||||
|
Baseline End of trial |
0.806 0.882 |
0.903 0.940 |
||||
P*: p-values for comparison within groups via paired t-test.
P**: p-values for comparison between groups via independent t-test.
P***: p-values based on an ANCOVA model adjusted with baseline value of the outcome, age, marital status, PCOS duration and mean changes in BMI, waist circumference and hip circumference.
CI: confidence interval